UCLA Radiation OncologyLos Angeles, CA
Disclosures:
2925 - Tolerability of Metastasis-Directed Stereotactic Body Radiotherapy with Short-Course Triple-Agent Androgen Annihilation Therapy in Recurrent Oligometastatic Prostate Cancer: Secondary Analysis of a Ph
Tuesday, October 3, 20232:30 PM – 3:45 PM PT
2926 - Predictive Value of Genomic Classifier Scores and Transcriptomic Data for Prostate Cancer Distant Metastasis Risk: A Multicenter Retrospective Study